NASDAQ$TXMD
TherapeuticsMD Inc · Q1 2020 earnings
Q1 2020 earnings · · Investor relations
Briefing
Reported financial results for the first quarter ended March 31, 2020.
TherapeuticsMD reported Q1 2020 financial results, with net product revenue of $12.3 million. The company significantly reduced operating expenses and is aiming for EBITDA breakeven in 2021. The launch of ANNOVERA was paused due to the COVID-19 pandemic.
- Total net product revenue for Q1 2020 was $12.3 million, exceeding Wall Street consensus.
- The company is significantly reducing operating expenses, while maintaining the goal of achieving EBITDA breakeven in 2021.
- Discussions are ongoing with TPG Sixth Street Partners to defer the scheduled start of quarterly revenue covenants due to COVID-19.
- The first Orange Book listed patent for ANNOVERA® was issued, potentially extending exclusivity to 2039.
Headline financials
Revenue & EPS history
TherapeuticsMD · Revenue · Quarterly
$12.3M
Forward guidance
The company expects total operating costs to be significantly reduced for the remainder of the year and net product revenue to improve.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2020
+0.4%
Avg return
Earnings day
-1.0%
Avg return
5 days after
+0.9%
Avg return
30 days after
38%
24 / 64 earnings
Positive
+200.0%
Q1 2011
Best reaction
-27.5%
Q4 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | -3.6% | -8.3% | +4.2% | |
| Q2 2025 | -0.9% | -2.7% | -1.8% | |
| Q1 2025 | -3.9% | -2.6% | -23.0% | |
| Q4 2024 | +6.1% | +20.9% | +26.1% | |
| Q3 2024 | -1.3% | -7.9% | -17.8% | |
| Q2 2024 | -1.2% | -4.0% | +2.9% | |
| Q1 2024 | +2.5% | +6.7% | -4.8% | |
| Q1 2026 | -1.9% | +6.7% | -4.8% | |
| Q4 2023 | +1.3% | -2.6% | -18.8% | |
| Q3 2023 | +17.1% | +12.4% | +18.3% | |
| Q2 2023 | -3.0% | -5.3% | -10.9% | |
| Q1 2023 | +0.2% | -1.6% | -13.9% | |
| Q4 2022 | +0.6% | +2.0% | +7.6% | |
| Q3 2022 | -15.0% | -27.8% | +0.3% | |
| Q2 2022 | +4.1% | +8.5% | -7.2% | |
| Q1 2022 | -12.1% | +1.0% | +223.1% | |
| Q4 2021 | -27.5% | -17.5% | -17.5% | |
| Q3 2021 | -12.5% | -18.1% | -37.5% | |
| Q2 2021 | -4.1% | -3.1% | -18.4% | |
| Q1 2021 | -14.8% | -18.7% | -5.5% | |
| Q4 2020 | +0.7% | -5.5% | -4.1% | |
| Q3 2020 | +10.7% | +0.8% | -4.9% | |
| Q2 2020 | -18.5% | -24.4% | -31.2% | |
| Q1 2020 | -5.8% | -5.8% | -15.1% | |
| Q4 2019 | -14.2% | -22.9% | -57.9% | |
| Q3 2019 | +4.1% | +5.2% | -10.3% | |
| Q2 2019 | +17.7% | +61.5% | +44.3% | |
| Q1 2019 | -12.8% | -20.9% | -26.8% | |
| Q4 2018 | -1.1% | +4.4% | -4.9% | |
| Q3 2018 | +6.0% | +0.4% | -3.4% | |
| Q2 2018 | -14.1% | -14.1% | +3.6% | |
| Q1 2018 | +2.2% | +4.9% | -0.7% | |
| Q4 2017 | -8.4% | -3.8% | -10.2% | |
| Q3 2017 | +27.8% | +30.0% | +33.0% | |
| Q2 2017 | -6.6% | -4.1% | +6.8% | |
| Q1 2017 | -6.4% | -6.8% | -12.2% | |
| Q4 2016 | +3.0% | +10.8% | +19.4% | |
| Q3 2016 | +0.0% | +10.5% | +19.7% | |
| Q2 2016 | +0.8% | +2.1% | -9.2% | |
| Q1 2016 | -5.8% | — | — | |
| Q4 2015 | +2.2% | — | — | |
| Q3 2015 | +2.2% | — | — | |
| Q2 2015 | -9.2% | — | — | |
| Q1 2015 | -11.6% | — | — | |
| Q4 2014 | +0.4% | — | — | |
| Q3 2014 | -15.3% | — | — | |
| Q2 2014 | +10.7% | — | — | |
| Q1 2014 | -9.0% | — | — | |
| Q4 2013 | +2.8% | — | — | |
| Q3 2013 | -10.0% | — | — | |
| Q2 2013 | -5.4% | — | — | |
| Q1 2013 | +0.4% | — | — | |
| Q4 2012 | -1.8% | — | — | |
| Q3 2012 | -8.7% | — | — | |
| Q2 2012 | +1.5% | — | — | |
| Q1 2012 | -2.0% | — | — | |
| Q4 2011 | -3.6% | — | — | |
| Q3 2011 | +0.0% | — | — | |
| Q2 2011 | +0.0% | — | — | |
| Q1 2011 | +200.0% | — | — | |
| Q4 2010 | -25.0% | — | — | |
| Q3 2010 | +0.0% | — | — | |
| Q2 2010 | +0.0% | — | — | |
| Q1 2010 | +0.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro